Abstract
Nasopharyngeal carcinoma (NPC) is a highly malignant and frequently metastasized tumor, and the prognosis is very poor when distant metastases occur. Recently, immunotherapy is becoming a promising therapeutic approach. Interferon-α (IFN-α) represents the cytokines exhibiting the longest record of use in clinical oncology. In this study, we examined the antitumor effects of IFN-α1b on NPC. The results showed that recombinant human IFN-α1b (hIFN-α1b) suppressed cell growth, induced a G1-phase cell cycle arrest in vitro, increased the expression of p16 and pRb, and decreased the expression of CCND1 and CDK6. In vivo analyses showed that either recombinant adeno-associated virus (rAAV)-IFN-α1b or hIFN-α1b treatment inhibited tumor growth and metastasis, reduced intratumoral microvessel density, increased cell apoptosis and necrosis, and induced prolonged survival. Notably, rAAV-IFN-α1b or hIFN-α1b treatment led to significantly higher serum levels of IL-12 and GM-CSF in mice compared to respective controls. Our findings suggest that IFN-α1b acts as a multifunctional antitumor agent in NPC, which may have important therapeutic implications.
Keywords: Cell growth, cytokine, immunotherapy, interferon-α1b, metastasis, nasopharyngeal carcinoma
Current Cancer Drug Targets
Title:Antitumor Effects of Interferon-Alpha on Cell Growth and Metastasis in Human Nasopharyngeal Carcinoma
Volume: 12 Issue: 5
Author(s): X. Liu, J. Lu, M.-L. He, Z. Li, B. Zhang, L.-H. Zhou, Q. Li, G. Li, L. Wang, W.-D. Tian, Y. Peng and X.-P. Li
Affiliation:
Keywords: Cell growth, cytokine, immunotherapy, interferon-α1b, metastasis, nasopharyngeal carcinoma
Abstract: Nasopharyngeal carcinoma (NPC) is a highly malignant and frequently metastasized tumor, and the prognosis is very poor when distant metastases occur. Recently, immunotherapy is becoming a promising therapeutic approach. Interferon-α (IFN-α) represents the cytokines exhibiting the longest record of use in clinical oncology. In this study, we examined the antitumor effects of IFN-α1b on NPC. The results showed that recombinant human IFN-α1b (hIFN-α1b) suppressed cell growth, induced a G1-phase cell cycle arrest in vitro, increased the expression of p16 and pRb, and decreased the expression of CCND1 and CDK6. In vivo analyses showed that either recombinant adeno-associated virus (rAAV)-IFN-α1b or hIFN-α1b treatment inhibited tumor growth and metastasis, reduced intratumoral microvessel density, increased cell apoptosis and necrosis, and induced prolonged survival. Notably, rAAV-IFN-α1b or hIFN-α1b treatment led to significantly higher serum levels of IL-12 and GM-CSF in mice compared to respective controls. Our findings suggest that IFN-α1b acts as a multifunctional antitumor agent in NPC, which may have important therapeutic implications.
Export Options
About this article
Cite this article as:
Liu X., Lu J., He M.-L., Li Z., Zhang B., Zhou L.-H., Li Q., Li G., Wang L., Tian W.-D., Peng Y. and Li X.-P., Antitumor Effects of Interferon-Alpha on Cell Growth and Metastasis in Human Nasopharyngeal Carcinoma, Current Cancer Drug Targets 2012; 12 (5) . https://dx.doi.org/10.2174/156800912800673293
DOI https://dx.doi.org/10.2174/156800912800673293 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immune Response and Immunotherapy: Live Attenuated Listeria monocytogenes (Lm)-LLO Immunotherapy for the Treatment of Prostate Cancer
Current Cancer Therapy Reviews Involvement of Targeting and Scaffolding Proteins in the Regulation of the EGFR/Ras/MAPK Pathway in Oncogenesis
Current Signal Transduction Therapy Cancer Gene Therapy with Tissue Inhibitors of Metalloproteinases (TIMPs)
Current Gene Therapy Melanoma
Current Cancer Therapy Reviews EGFR(s) in Aging and Carcinogenesis of the Gastrointestinal Tract
Current Protein & Peptide Science Key Questions in Metastasis: New Insights in Molecular Pathways and Therapeutic Implications
Current Pharmaceutical Biotechnology Synthesis and Anti-tumor Activities of Novel Phenyl Substituted Suberoylanilide Hydroxamic Acid Derivatives Against Human Cancer Cells
Medicinal Chemistry An Unbiased Predictive Model to Detect DNA Methylation Propensity of CpG Islands in the Human Genome
Current Bioinformatics Patent Selections
Recent Patents on Biomarkers Developments in Thermometry from 1984 to 2011: A Review
Recent Patents on Mechanical Engineering Upfront DPD Deficiency Detection to Secure 5-FU Administration: Part 1 – Where Do We Stand?
Clinical Cancer Drugs Genomic and Cellular Pathology of Lung Cancer
Current Respiratory Medicine Reviews A Search for Inhibitors of S100B, a Member of the S100 Family of Calcium-Binding Proteins
Mini-Reviews in Medicinal Chemistry Phytochemicals as PI3K/ Akt/ mTOR Inhibitors and Their Role in Breast Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Anticancer Potential of Dietary Natural Products: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry Patent Selections
Recent Patents on Biomarkers Tumor-Targeting Peptides: Ligands for Molecular Imaging and Therapy
Anti-Cancer Agents in Medicinal Chemistry Validated RP-HPLC Method for the Simultaneous Analysis of Gemcitabine and LY-364947 in Liposomal Formulations
Current Drug Targets A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness
Anti-Cancer Agents in Medicinal Chemistry HSV-1-Derived Recombinant and Amplicon Vectors for Gene Transfer and Gene Therapy
Current Gene Therapy